Minister Jeong Eun-kyeong, alopecia reimb·convenience store OTC discussions

Internal financial impact assessments of President Lee Jae Myung's campaign pledge 'insurance coverage for alopecia therapeutics' have been completed

Officializing the agenda of expanding over-the-counter (OTC) drugs in convenience stores to twenty items· prescription drug deliveries

Plans for highly contentious regulatory issues…political insiders "a calculated tactical play"

Attention is drawn to the Ministry of Health and Welfare (MOHW) as Minister Jeong Eun-kyeong announces a policy push on previously postponed healthcare agendas, marking the first anniversary of the current administration.  Minister Jeong has unveiled key strategic priorities for the second half of the year.

Industry analysis suggests that the policy push on highly contentious regulatory issues represents a strategic measure by Minister Jeong to avoid criticisms regarding a perceived deficit in impactful policy performance occasionally raised within political circles and the presidential office.

On June 14, Minister Jeong brought major industry discussions by incorporating high-stakes agendas to the forefront of the ministry’s second-half project, explicitly outlining plans to expand national health insurance reimbursement for ▲alopecia treatments ▲broaden the retail formulary for over-the-counter (OTC) drugs in convenience stores ▲scale up home delivery frameworks for prescription medications under the non-face-to-face treatment system.  

Notably, attention is drawn to the expansion of National Health Insurance coverage for anti-alopecia therapeutics, a high-profile campaign pledge championed by President Lee Jae Myung that previously triggered intense public discourse.

President Lee had previously committed to the reimbursement expansion by addressing the discomfort by the younger male demographic, arguing that alopecia extends far beyond aesthetic concerns to induce depression, social anxiety, and diminished self-esteem, thereby qualifying it as a clinically treatable condition impacting foundational health.

However, the MOHW maintained a neutral stance amid fierce counterarguments questioning the fiscal rationale for subsidizing alopecia treatments, given that finite state reimbursement reserves are chronically underfunded to cover high-priority oncology and orphan drugs for rare, intractable diseases.  

Minister Jeong announced that the MOH and the Ministry of the Interior and Safety will host the inaugural 'Public Deliberation Forum' on July 4 to examine the integration of alopecia drugs into the health insurance system.

This forum represents an official public consultation process. Expert presentations will precede extensive citizen-led focus panels to gauge broader societal consensus. 

Minister Jeong confirmed that "internal financial impact assessments evaluated the required fiscal expenditures from the national health insurance budget have already been completed. "

Government insiders interpret this aggressive signaling as a calculated alignment with the presidential office, elevating the execution of key campaign pledges to the top of the second-half ministerial project to showcase decisive executive momentum.

Furthermore, Minister Jeong addressed both convenience-store OTC drug availability and remote prescription delivery initiatives, two highly volatile portfolios in which the MOHW had maintained a cautious approach amid heavy pushback from influential pharmacist advocacy groups.  

For retail OTC drug distribution, Minister Jeong explicitly committed to a second-half legislative push to expand the current 11-item convenience store formulary to a maximum of 20 products, while concurrently lowering operational barriers, such as the mandatory 24-hour business requirement for participating convenience stores.

With relevant revisions currently stalled in the National Assembly’s Health and Welfare Committee, the Minister's explicit public backing is expected to push strong legislative momentum to clear the subcommittee review phase during the latter half of the year.

Regarding non-face-to-face treatments scheduled for implementation on December 26, the policy blueprint specifically mandated the 'stabilization and expansion of prescription drug delivery system'.

This indicates that the administration intends to leverage the promulgation of enforcement decrees to radically broaden the eligibility criteria for home medication delivery, which is currently restricted to highly isolated island residents and designated rare disease cohorts.

Industry insiders view the sudden escalation of multiple systemic flashpoints, guaranteed to provoke fierce blowback from the medical and pharmaceutical professions, as a decisive move to remove the ministerial 'underperformance' label that has previously shadowed the Minister's tenure.  

A political insider commented, "Minister Jeong is shifting from a cautious defensive posture to articulating unambiguous stances on structural reforms," and added, "Amid raised speculation regarding a potential cabinet reshuffle, this serves as a calculated tactical play to project external policy achievements by aggressively prioritizing presidential priorities."

Furthermore, "This coincides with the presidential office's intensive audit of ministerial operational metrics and separate tracking of campaign pledge execution timelines," and added, "It functions as a direct response to the ruling party's demands for tangible milestones, while allowing Minister Jeong to project decisive legislative breakthrough capacity over stagnant healthcare files."